nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—SLC6A3—malignant glioma	0.806	1	CbGaD
Methylphenidate—Reaction aggravation—Carmustine—malignant glioma	0.0119	0.0743	CcSEcCtD
Methylphenidate—Adverse reaction—Carmustine—malignant glioma	0.0119	0.0743	CcSEcCtD
Methylphenidate—SLC6A3—telencephalic ventricle—malignant glioma	0.00474	0.228	CbGeAlD
Methylphenidate—Abnormal behaviour—Temozolomide—malignant glioma	0.00323	0.0202	CcSEcCtD
Methylphenidate—Personality disorder—Carmustine—malignant glioma	0.00288	0.018	CcSEcCtD
Methylphenidate—Grand mal convulsion—Carmustine—malignant glioma	0.00261	0.0164	CcSEcCtD
Methylphenidate—Cerebral haemorrhage—Carmustine—malignant glioma	0.00225	0.0141	CcSEcCtD
Methylphenidate—Cerebral haemorrhage—Temozolomide—malignant glioma	0.00217	0.0136	CcSEcCtD
Methylphenidate—Skin hyperpigmentation—Carmustine—malignant glioma	0.00209	0.0131	CcSEcCtD
Methylphenidate—Haemorrhoids—Temozolomide—malignant glioma	0.00205	0.0128	CcSEcCtD
Methylphenidate—Apathy—Temozolomide—malignant glioma	0.00168	0.0105	CcSEcCtD
Methylphenidate—Flat affect—Temozolomide—malignant glioma	0.00167	0.0104	CcSEcCtD
Methylphenidate—Dexmethylphenidate—SLC6A3—malignant glioma	0.00159	0.53	CrCbGaD
Methylphenidate—Abscess—Carmustine—malignant glioma	0.00157	0.00985	CcSEcCtD
Methylphenidate—Otitis media—Temozolomide—malignant glioma	0.00154	0.00967	CcSEcCtD
Methylphenidate—Petechiae—Temozolomide—malignant glioma	0.00146	0.00915	CcSEcCtD
Methylphenidate—Speech disorder—Carmustine—malignant glioma	0.00145	0.00906	CcSEcCtD
Methylphenidate—Cyclopentolate—BCHE—malignant glioma	0.00141	0.469	CrCbGaD
Methylphenidate—Accidental injury—Carmustine—malignant glioma	0.00141	0.00881	CcSEcCtD
Methylphenidate—Speech disorder—Temozolomide—malignant glioma	0.0014	0.00875	CcSEcCtD
Methylphenidate—Thinking abnormal—Carmustine—malignant glioma	0.00136	0.00851	CcSEcCtD
Methylphenidate—Drug interaction—Carmustine—malignant glioma	0.00134	0.0084	CcSEcCtD
Methylphenidate—SLC6A3—brainstem—malignant glioma	0.00128	0.0617	CbGeAlD
Methylphenidate—Hepatic enzyme increased—Temozolomide—malignant glioma	0.00127	0.00796	CcSEcCtD
Methylphenidate—Neck pain—Carmustine—malignant glioma	0.00126	0.00789	CcSEcCtD
Methylphenidate—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.0012	0.00753	CcSEcCtD
Methylphenidate—Skin exfoliation—Carmustine—malignant glioma	0.00119	0.00744	CcSEcCtD
Methylphenidate—SLC6A4—brainstem—malignant glioma	0.00118	0.0565	CbGeAlD
Methylphenidate—Skin exfoliation—Temozolomide—malignant glioma	0.00115	0.00719	CcSEcCtD
Methylphenidate—SLC6A3—telencephalon—malignant glioma	0.00114	0.0547	CbGeAlD
Methylphenidate—Coma—Carmustine—malignant glioma	0.00114	0.00712	CcSEcCtD
Methylphenidate—Aplastic anaemia—Temozolomide—malignant glioma	0.00113	0.00707	CcSEcCtD
Methylphenidate—Neoplasm—Carmustine—malignant glioma	0.00113	0.00705	CcSEcCtD
Methylphenidate—Gynaecomastia—Carmustine—malignant glioma	0.00111	0.00697	CcSEcCtD
Methylphenidate—Dry eye—Temozolomide—malignant glioma	0.00111	0.00696	CcSEcCtD
Methylphenidate—Neoplasm—Temozolomide—malignant glioma	0.00109	0.00681	CcSEcCtD
Methylphenidate—Abnormal vision—Carmustine—malignant glioma	0.00109	0.0068	CcSEcCtD
Methylphenidate—Mental disability—Carmustine—malignant glioma	0.00108	0.00676	CcSEcCtD
Methylphenidate—Abnormal vision—Temozolomide—malignant glioma	0.00105	0.00657	CcSEcCtD
Methylphenidate—Mental disability—Temozolomide—malignant glioma	0.00104	0.00653	CcSEcCtD
Methylphenidate—SLC6A4—telencephalon—malignant glioma	0.00104	0.0502	CbGeAlD
Methylphenidate—Diabetes mellitus—Carmustine—malignant glioma	0.00104	0.0065	CcSEcCtD
Methylphenidate—SLC6A2—brainstem—malignant glioma	0.00103	0.0498	CbGeAlD
Methylphenidate—Swelling—Carmustine—malignant glioma	0.00102	0.00641	CcSEcCtD
Methylphenidate—Ear pain—Temozolomide—malignant glioma	0.00102	0.00641	CcSEcCtD
Methylphenidate—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.001	0.00628	CcSEcCtD
Methylphenidate—Eye pain—Carmustine—malignant glioma	0.001	0.00627	CcSEcCtD
Methylphenidate—Gastroenteritis—Temozolomide—malignant glioma	0.000985	0.00617	CcSEcCtD
Methylphenidate—Injury—Carmustine—malignant glioma	0.000983	0.00615	CcSEcCtD
Methylphenidate—Eye pain—Temozolomide—malignant glioma	0.000967	0.00605	CcSEcCtD
Methylphenidate—Nasal congestion—Temozolomide—malignant glioma	0.000958	0.006	CcSEcCtD
Methylphenidate—Hot flush—Temozolomide—malignant glioma	0.000933	0.00584	CcSEcCtD
Methylphenidate—Dermatitis exfoliative—Temozolomide—malignant glioma	0.000925	0.00579	CcSEcCtD
Methylphenidate—Menopausal symptoms—Temozolomide—malignant glioma	0.000925	0.00579	CcSEcCtD
Methylphenidate—SLC6A2—telencephalon—malignant glioma	0.000919	0.0442	CbGeAlD
Methylphenidate—Thirst—Temozolomide—malignant glioma	0.000917	0.00574	CcSEcCtD
Methylphenidate—Diplopia—Carmustine—malignant glioma	0.000904	0.00566	CcSEcCtD
Methylphenidate—Diplopia—Temozolomide—malignant glioma	0.000873	0.00547	CcSEcCtD
Methylphenidate—Affect lability—Temozolomide—malignant glioma	0.000859	0.00538	CcSEcCtD
Methylphenidate—Liver function test abnormal—Carmustine—malignant glioma	0.000834	0.00522	CcSEcCtD
Methylphenidate—Mood swings—Temozolomide—malignant glioma	0.000827	0.00518	CcSEcCtD
Methylphenidate—SLC6A3—midbrain—malignant glioma	0.000818	0.0393	CbGeAlD
Methylphenidate—Dehydration—Temozolomide—malignant glioma	0.000812	0.00508	CcSEcCtD
Methylphenidate—SLC6A3—spinal cord—malignant glioma	0.000798	0.0383	CbGeAlD
Methylphenidate—Breast disorder—Temozolomide—malignant glioma	0.000789	0.00494	CcSEcCtD
Methylphenidate—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.00077	0.00482	CcSEcCtD
Methylphenidate—SLC6A4—midbrain—malignant glioma	0.000749	0.036	CbGeAlD
Methylphenidate—Pancytopenia—Carmustine—malignant glioma	0.000742	0.00464	CcSEcCtD
Methylphenidate—SLC6A4—spinal cord—malignant glioma	0.000731	0.0351	CbGeAlD
Methylphenidate—Bronchitis—Temozolomide—malignant glioma	0.000726	0.00454	CcSEcCtD
Methylphenidate—SLC6A2—medulla oblongata—malignant glioma	0.000722	0.0347	CbGeAlD
Methylphenidate—Pancytopenia—Temozolomide—malignant glioma	0.000717	0.00449	CcSEcCtD
Methylphenidate—Upper respiratory tract infection—Temozolomide—malignant glioma	0.000701	0.00439	CcSEcCtD
Methylphenidate—Pneumonia—Carmustine—malignant glioma	0.0007	0.00438	CcSEcCtD
Methylphenidate—Erectile dysfunction—Temozolomide—malignant glioma	0.000695	0.00435	CcSEcCtD
Methylphenidate—Depression—Carmustine—malignant glioma	0.000694	0.00435	CcSEcCtD
Methylphenidate—Photosensitivity reaction—Temozolomide—malignant glioma	0.000689	0.00431	CcSEcCtD
Methylphenidate—Weight increased—Temozolomide—malignant glioma	0.000687	0.0043	CcSEcCtD
Methylphenidate—Weight decreased—Temozolomide—malignant glioma	0.000683	0.00427	CcSEcCtD
Methylphenidate—Pneumonia—Temozolomide—malignant glioma	0.000677	0.00424	CcSEcCtD
Methylphenidate—Infestation—Temozolomide—malignant glioma	0.000673	0.00421	CcSEcCtD
Methylphenidate—Infestation NOS—Temozolomide—malignant glioma	0.000673	0.00421	CcSEcCtD
Methylphenidate—Depression—Temozolomide—malignant glioma	0.000671	0.0042	CcSEcCtD
Methylphenidate—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000667	0.00418	CcSEcCtD
Methylphenidate—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—malignant glioma	0.000661	0.0639	CbGpPWpGaD
Methylphenidate—SLC6A3—central nervous system—malignant glioma	0.000647	0.0311	CbGeAlD
Methylphenidate—Hepatobiliary disease—Temozolomide—malignant glioma	0.000636	0.00398	CcSEcCtD
Methylphenidate—SLC6A3—cerebellum—malignant glioma	0.000632	0.0304	CbGeAlD
Methylphenidate—Sinusitis—Temozolomide—malignant glioma	0.000631	0.00395	CcSEcCtD
Methylphenidate—Haemoglobin—Carmustine—malignant glioma	0.000628	0.00393	CcSEcCtD
Methylphenidate—Haemorrhage—Carmustine—malignant glioma	0.000625	0.00391	CcSEcCtD
Methylphenidate—Hallucination—Carmustine—malignant glioma	0.000622	0.00389	CcSEcCtD
Methylphenidate—Connective tissue disorder—Carmustine—malignant glioma	0.000614	0.00385	CcSEcCtD
Methylphenidate—Haemoglobin—Temozolomide—malignant glioma	0.000607	0.0038	CcSEcCtD
Methylphenidate—Haemorrhage—Temozolomide—malignant glioma	0.000604	0.00378	CcSEcCtD
Methylphenidate—Visual impairment—Carmustine—malignant glioma	0.000602	0.00377	CcSEcCtD
Methylphenidate—Hallucination—Temozolomide—malignant glioma	0.000601	0.00376	CcSEcCtD
Methylphenidate—Pharyngitis—Temozolomide—malignant glioma	0.000599	0.00375	CcSEcCtD
Methylphenidate—SLC6A4—Synaptic Vesicle Pathway—SYP—malignant glioma	0.000598	0.0578	CbGpPWpGaD
Methylphenidate—Urinary tract disorder—Temozolomide—malignant glioma	0.000597	0.00373	CcSEcCtD
Methylphenidate—Connective tissue disorder—Temozolomide—malignant glioma	0.000594	0.00372	CcSEcCtD
Methylphenidate—SLC6A4—central nervous system—malignant glioma	0.000593	0.0285	CbGeAlD
Methylphenidate—Urethral disorder—Temozolomide—malignant glioma	0.000592	0.00371	CcSEcCtD
Methylphenidate—Eye disorder—Carmustine—malignant glioma	0.000584	0.00366	CcSEcCtD
Methylphenidate—Visual impairment—Temozolomide—malignant glioma	0.000582	0.00364	CcSEcCtD
Methylphenidate—Flushing—Carmustine—malignant glioma	0.00058	0.00363	CcSEcCtD
Methylphenidate—Erythema multiforme—Temozolomide—malignant glioma	0.000571	0.00358	CcSEcCtD
Methylphenidate—CYP2D6—brainstem—malignant glioma	0.000567	0.0272	CbGeAlD
Methylphenidate—Eye disorder—Temozolomide—malignant glioma	0.000564	0.00353	CcSEcCtD
Methylphenidate—Cardiac disorder—Temozolomide—malignant glioma	0.000561	0.00351	CcSEcCtD
Methylphenidate—Flushing—Temozolomide—malignant glioma	0.000561	0.00351	CcSEcCtD
Methylphenidate—Arrhythmia—Carmustine—malignant glioma	0.000558	0.0035	CcSEcCtD
Methylphenidate—Alopecia—Carmustine—malignant glioma	0.000552	0.00346	CcSEcCtD
Methylphenidate—Angiopathy—Temozolomide—malignant glioma	0.000548	0.00343	CcSEcCtD
Methylphenidate—Mental disorder—Carmustine—malignant glioma	0.000548	0.00343	CcSEcCtD
Methylphenidate—Immune system disorder—Temozolomide—malignant glioma	0.000546	0.00342	CcSEcCtD
Methylphenidate—Mediastinal disorder—Temozolomide—malignant glioma	0.000544	0.00341	CcSEcCtD
Methylphenidate—Erythema—Carmustine—malignant glioma	0.000544	0.00341	CcSEcCtD
Methylphenidate—Malnutrition—Carmustine—malignant glioma	0.000544	0.00341	CcSEcCtD
Methylphenidate—Chills—Temozolomide—malignant glioma	0.000542	0.00339	CcSEcCtD
Methylphenidate—Alopecia—Temozolomide—malignant glioma	0.000534	0.00334	CcSEcCtD
Methylphenidate—Mental disorder—Temozolomide—malignant glioma	0.000529	0.00331	CcSEcCtD
Methylphenidate—Back pain—Carmustine—malignant glioma	0.000526	0.00329	CcSEcCtD
Methylphenidate—Erythema—Temozolomide—malignant glioma	0.000526	0.00329	CcSEcCtD
Methylphenidate—Malnutrition—Temozolomide—malignant glioma	0.000526	0.00329	CcSEcCtD
Methylphenidate—SLC6A2—central nervous system—malignant glioma	0.000522	0.0251	CbGeAlD
Methylphenidate—SLC6A3—brain—malignant glioma	0.000514	0.0247	CbGeAlD
Methylphenidate—Vision blurred—Carmustine—malignant glioma	0.000513	0.00321	CcSEcCtD
Methylphenidate—Tremor—Carmustine—malignant glioma	0.00051	0.00319	CcSEcCtD
Methylphenidate—Back pain—Temozolomide—malignant glioma	0.000509	0.00318	CcSEcCtD
Methylphenidate—CYP2D6—telencephalon—malignant glioma	0.000503	0.0242	CbGeAlD
Methylphenidate—Anaemia—Carmustine—malignant glioma	0.000503	0.00315	CcSEcCtD
Methylphenidate—Agitation—Carmustine—malignant glioma	0.0005	0.00313	CcSEcCtD
Methylphenidate—Vision blurred—Temozolomide—malignant glioma	0.000496	0.0031	CcSEcCtD
Methylphenidate—Tremor—Temozolomide—malignant glioma	0.000493	0.00308	CcSEcCtD
Methylphenidate—Ill-defined disorder—Temozolomide—malignant glioma	0.000488	0.00305	CcSEcCtD
Methylphenidate—Leukopenia—Carmustine—malignant glioma	0.000487	0.00305	CcSEcCtD
Methylphenidate—Anaemia—Temozolomide—malignant glioma	0.000486	0.00304	CcSEcCtD
Methylphenidate—Agitation—Temozolomide—malignant glioma	0.000483	0.00303	CcSEcCtD
Methylphenidate—Angioedema—Temozolomide—malignant glioma	0.00048	0.00301	CcSEcCtD
Methylphenidate—Malaise—Temozolomide—malignant glioma	0.000474	0.00297	CcSEcCtD
Methylphenidate—Vertigo—Temozolomide—malignant glioma	0.000472	0.00296	CcSEcCtD
Methylphenidate—Convulsion—Carmustine—malignant glioma	0.000471	0.00295	CcSEcCtD
Methylphenidate—SLC6A4—brain—malignant glioma	0.000471	0.0226	CbGeAlD
Methylphenidate—Leukopenia—Temozolomide—malignant glioma	0.000471	0.00295	CcSEcCtD
Methylphenidate—Hypertension—Carmustine—malignant glioma	0.00047	0.00294	CcSEcCtD
Methylphenidate—Palpitations—Temozolomide—malignant glioma	0.000465	0.00291	CcSEcCtD
Methylphenidate—Myalgia—Carmustine—malignant glioma	0.000463	0.0029	CcSEcCtD
Methylphenidate—Chest pain—Carmustine—malignant glioma	0.000463	0.0029	CcSEcCtD
Methylphenidate—Anxiety—Carmustine—malignant glioma	0.000462	0.00289	CcSEcCtD
Methylphenidate—Cough—Temozolomide—malignant glioma	0.000459	0.00287	CcSEcCtD
Methylphenidate—Convulsion—Temozolomide—malignant glioma	0.000456	0.00285	CcSEcCtD
Methylphenidate—Hypertension—Temozolomide—malignant glioma	0.000454	0.00284	CcSEcCtD
Methylphenidate—Confusional state—Carmustine—malignant glioma	0.000448	0.0028	CcSEcCtD
Methylphenidate—Myalgia—Temozolomide—malignant glioma	0.000448	0.0028	CcSEcCtD
Methylphenidate—Arthralgia—Temozolomide—malignant glioma	0.000448	0.0028	CcSEcCtD
Methylphenidate—Anxiety—Temozolomide—malignant glioma	0.000446	0.00279	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000445	0.00278	CcSEcCtD
Methylphenidate—Oedema—Carmustine—malignant glioma	0.000444	0.00278	CcSEcCtD
Methylphenidate—Discomfort—Temozolomide—malignant glioma	0.000442	0.00277	CcSEcCtD
Methylphenidate—Infection—Carmustine—malignant glioma	0.000441	0.00276	CcSEcCtD
Methylphenidate—Dry mouth—Temozolomide—malignant glioma	0.000438	0.00274	CcSEcCtD
Methylphenidate—Thrombocytopenia—Carmustine—malignant glioma	0.000435	0.00272	CcSEcCtD
Methylphenidate—Tachycardia—Carmustine—malignant glioma	0.000433	0.00271	CcSEcCtD
Methylphenidate—Confusional state—Temozolomide—malignant glioma	0.000433	0.00271	CcSEcCtD
Methylphenidate—Anaphylactic shock—Temozolomide—malignant glioma	0.000429	0.00269	CcSEcCtD
Methylphenidate—Oedema—Temozolomide—malignant glioma	0.000429	0.00269	CcSEcCtD
Methylphenidate—Infection—Temozolomide—malignant glioma	0.000426	0.00267	CcSEcCtD
Methylphenidate—Anorexia—Carmustine—malignant glioma	0.000423	0.00265	CcSEcCtD
Methylphenidate—Nervous system disorder—Temozolomide—malignant glioma	0.000421	0.00263	CcSEcCtD
Methylphenidate—Thrombocytopenia—Temozolomide—malignant glioma	0.00042	0.00263	CcSEcCtD
Methylphenidate—Skin disorder—Temozolomide—malignant glioma	0.000417	0.00261	CcSEcCtD
Methylphenidate—Hyperhidrosis—Temozolomide—malignant glioma	0.000415	0.0026	CcSEcCtD
Methylphenidate—SLC6A2—brain—malignant glioma	0.000414	0.0199	CbGeAlD
Methylphenidate—Anorexia—Temozolomide—malignant glioma	0.000409	0.00256	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000405	0.00253	CcSEcCtD
Methylphenidate—Insomnia—Carmustine—malignant glioma	0.000402	0.00251	CcSEcCtD
Methylphenidate—Paraesthesia—Carmustine—malignant glioma	0.000399	0.0025	CcSEcCtD
Methylphenidate—Dyspnoea—Carmustine—malignant glioma	0.000396	0.00248	CcSEcCtD
Methylphenidate—Somnolence—Carmustine—malignant glioma	0.000395	0.00247	CcSEcCtD
Methylphenidate—CYP2D6—CYP2E1 reactions—CYP2B6—malignant glioma	0.000393	0.038	CbGpPWpGaD
Methylphenidate—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000391	0.00245	CcSEcCtD
Methylphenidate—Insomnia—Temozolomide—malignant glioma	0.000388	0.00243	CcSEcCtD
Methylphenidate—Decreased appetite—Carmustine—malignant glioma	0.000386	0.00242	CcSEcCtD
Methylphenidate—Paraesthesia—Temozolomide—malignant glioma	0.000385	0.00241	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Carmustine—malignant glioma	0.000383	0.0024	CcSEcCtD
Methylphenidate—Dyspnoea—Temozolomide—malignant glioma	0.000383	0.0024	CcSEcCtD
Methylphenidate—Somnolence—Temozolomide—malignant glioma	0.000382	0.00239	CcSEcCtD
Methylphenidate—Pain—Carmustine—malignant glioma	0.00038	0.00238	CcSEcCtD
Methylphenidate—Constipation—Carmustine—malignant glioma	0.00038	0.00238	CcSEcCtD
Methylphenidate—Dyspepsia—Temozolomide—malignant glioma	0.000378	0.00236	CcSEcCtD
Methylphenidate—Decreased appetite—Temozolomide—malignant glioma	0.000373	0.00234	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00037	0.00232	CcSEcCtD
Methylphenidate—Fatigue—Temozolomide—malignant glioma	0.00037	0.00232	CcSEcCtD
Methylphenidate—Pain—Temozolomide—malignant glioma	0.000367	0.0023	CcSEcCtD
Methylphenidate—Constipation—Temozolomide—malignant glioma	0.000367	0.0023	CcSEcCtD
Methylphenidate—Feeling abnormal—Carmustine—malignant glioma	0.000366	0.00229	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Carmustine—malignant glioma	0.000363	0.00227	CcSEcCtD
Methylphenidate—Feeling abnormal—Temozolomide—malignant glioma	0.000354	0.00221	CcSEcCtD
Methylphenidate—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—malignant glioma	0.000351	0.0339	CbGpPWpGaD
Methylphenidate—Abdominal pain—Carmustine—malignant glioma	0.000351	0.0022	CcSEcCtD
Methylphenidate—Body temperature increased—Carmustine—malignant glioma	0.000351	0.0022	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Temozolomide—malignant glioma	0.000351	0.0022	CcSEcCtD
Methylphenidate—Urticaria—Temozolomide—malignant glioma	0.000341	0.00213	CcSEcCtD
Methylphenidate—Body temperature increased—Temozolomide—malignant glioma	0.000339	0.00212	CcSEcCtD
Methylphenidate—Abdominal pain—Temozolomide—malignant glioma	0.000339	0.00212	CcSEcCtD
Methylphenidate—Hypersensitivity—Carmustine—malignant glioma	0.000327	0.00205	CcSEcCtD
Methylphenidate—Asthenia—Carmustine—malignant glioma	0.000319	0.00199	CcSEcCtD
Methylphenidate—Hypersensitivity—Temozolomide—malignant glioma	0.000316	0.00198	CcSEcCtD
Methylphenidate—Asthenia—Temozolomide—malignant glioma	0.000308	0.00193	CcSEcCtD
Methylphenidate—CYP2D6—Fatty acids—CYP2B6—malignant glioma	0.000307	0.0296	CbGpPWpGaD
Methylphenidate—Diarrhoea—Carmustine—malignant glioma	0.000304	0.0019	CcSEcCtD
Methylphenidate—Pruritus—Temozolomide—malignant glioma	0.000304	0.0019	CcSEcCtD
Methylphenidate—SLC6A3—Dopaminergic Neurogenesis—SOX2—malignant glioma	0.000303	0.0293	CbGpPWpGaD
Methylphenidate—Dizziness—Carmustine—malignant glioma	0.000294	0.00184	CcSEcCtD
Methylphenidate—Diarrhoea—Temozolomide—malignant glioma	0.000294	0.00184	CcSEcCtD
Methylphenidate—SLC6A3—Alpha-synuclein signaling—PARK2—malignant glioma	0.000293	0.0283	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—POR—malignant glioma	0.000287	0.0277	CbGpPWpGaD
Methylphenidate—CYP2D6—central nervous system—malignant glioma	0.000286	0.0137	CbGeAlD
Methylphenidate—Dizziness—Temozolomide—malignant glioma	0.000284	0.00178	CcSEcCtD
Methylphenidate—Vomiting—Carmustine—malignant glioma	0.000282	0.00177	CcSEcCtD
Methylphenidate—Rash—Carmustine—malignant glioma	0.00028	0.00175	CcSEcCtD
Methylphenidate—Dermatitis—Carmustine—malignant glioma	0.00028	0.00175	CcSEcCtD
Methylphenidate—CYP2D6—cerebellum—malignant glioma	0.000279	0.0134	CbGeAlD
Methylphenidate—Headache—Carmustine—malignant glioma	0.000278	0.00174	CcSEcCtD
Methylphenidate—Vomiting—Temozolomide—malignant glioma	0.000273	0.00171	CcSEcCtD
Methylphenidate—Rash—Temozolomide—malignant glioma	0.000271	0.00169	CcSEcCtD
Methylphenidate—Dermatitis—Temozolomide—malignant glioma	0.00027	0.00169	CcSEcCtD
Methylphenidate—SLC6A4—Monoamine Transport—SLC6A3—malignant glioma	0.000269	0.026	CbGpPWpGaD
Methylphenidate—Headache—Temozolomide—malignant glioma	0.000269	0.00168	CcSEcCtD
Methylphenidate—Nausea—Carmustine—malignant glioma	0.000264	0.00165	CcSEcCtD
Methylphenidate—SLC6A4—Serotonin Transporter Activity—IL1B—malignant glioma	0.000258	0.0249	CbGpPWpGaD
Methylphenidate—Nausea—Temozolomide—malignant glioma	0.000255	0.0016	CcSEcCtD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—PARK2—malignant glioma	0.000249	0.024	CbGpPWpGaD
Methylphenidate—SLC6A2—Amine compound SLC transporters—SLC6A3—malignant glioma	0.000244	0.0236	CbGpPWpGaD
Methylphenidate—CYP2D6—Xenobiotics—CYP2B6—malignant glioma	0.000244	0.0235	CbGpPWpGaD
Methylphenidate—SLC6A2—Monoamine Transport—SLC6A3—malignant glioma	0.000232	0.0224	CbGpPWpGaD
Methylphenidate—CYP2D6—brain—malignant glioma	0.000227	0.0109	CbGeAlD
Methylphenidate—CYP2D6—Xenobiotics—CYP2C18—malignant glioma	0.000211	0.0204	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—FTH1—malignant glioma	0.00021	0.0203	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—FTH1—malignant glioma	0.000181	0.0175	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—FTH1—malignant glioma	0.00016	0.0155	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—NTRK3—malignant glioma	0.000151	0.0146	CbGpPWpGaD
Methylphenidate—SLC6A3—Alpha-synuclein signaling—BAD—malignant glioma	0.000125	0.0121	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—RUNX3—malignant glioma	0.000119	0.0115	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—MYB—malignant glioma	0.00011	0.0106	CbGpPWpGaD
Methylphenidate—SLC6A4—Monoamine Transport—IL1B—malignant glioma	0.00011	0.0106	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—SOX2—malignant glioma	0.000106	0.0103	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2B6—malignant glioma	0.000101	0.00977	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP2B6—malignant glioma	9.98e-05	0.00965	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—APOD—malignant glioma	9.68e-05	0.00935	CbGpPWpGaD
Methylphenidate—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—malignant glioma	9.53e-05	0.00921	CbGpPWpGaD
Methylphenidate—SLC6A2—Monoamine Transport—IL1B—malignant glioma	9.44e-05	0.00912	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2C18—malignant glioma	8.77e-05	0.00847	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP2C18—malignant glioma	8.66e-05	0.00836	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—APOD—malignant glioma	8.58e-05	0.00829	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—SLC5A5—malignant glioma	8.4e-05	0.00811	CbGpPWpGaD
Methylphenidate—SLC6A3—Monoamine Transport—IL1B—malignant glioma	8.37e-05	0.00808	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—YWHAE—malignant glioma	8.27e-05	0.00799	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—NTRK2—malignant glioma	8.27e-05	0.00799	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP2B6—malignant glioma	8.2e-05	0.00792	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—SLC6A3—malignant glioma	7.99e-05	0.00772	CbGpPWpGaD
Methylphenidate—SLC6A4—Monoamine Transport—TNF—malignant glioma	7.97e-05	0.0077	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PML—malignant glioma	7.74e-05	0.00748	CbGpPWpGaD
Methylphenidate—SLC6A3—Dopaminergic Neurogenesis—STAT3—malignant glioma	7.38e-05	0.00713	CbGpPWpGaD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—CASP3—malignant glioma	7.27e-05	0.00703	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—SLC5A5—malignant glioma	7.22e-05	0.00698	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP2C18—malignant glioma	7.11e-05	0.00687	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—TOP2A—malignant glioma	7.08e-05	0.00684	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—SLC6A3—malignant glioma	6.87e-05	0.00664	CbGpPWpGaD
Methylphenidate—SLC6A2—Monoamine Transport—TNF—malignant glioma	6.85e-05	0.00662	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—GJA1—malignant glioma	6.8e-05	0.00657	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—GSTP1—malignant glioma	6.76e-05	0.00654	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—SLC5A5—malignant glioma	6.4e-05	0.00618	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—COX8A—malignant glioma	6.33e-05	0.00611	CbGpPWpGaD
Methylphenidate—SLC6A3—Monoamine Transport—TNF—malignant glioma	6.07e-05	0.00586	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—HES1—malignant glioma	5.93e-05	0.00573	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTP1—malignant glioma	5.82e-05	0.00562	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—FTH1—malignant glioma	5.79e-05	0.00559	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—COX8A—malignant glioma	5.6e-05	0.00541	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—NTRK1—malignant glioma	5.51e-05	0.00532	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—malignant glioma	5.39e-05	0.00521	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—PDGFB—malignant glioma	5.35e-05	0.00517	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTP1—malignant glioma	5.15e-05	0.00498	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—FTH1—malignant glioma	5.13e-05	0.00495	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ATP1B2—malignant glioma	5.06e-05	0.00489	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—BCHE—malignant glioma	5.04e-05	0.00486	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—HIF1A—malignant glioma	4.97e-05	0.0048	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—APOD—malignant glioma	4.92e-05	0.00475	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—NCOR1—malignant glioma	4.81e-05	0.00465	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—PDGFB—malignant glioma	4.6e-05	0.00444	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—malignant glioma	4.55e-05	0.0044	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ATP1B2—malignant glioma	4.48e-05	0.00433	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—APOD—malignant glioma	4.36e-05	0.00421	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP2B6—malignant glioma	4.36e-05	0.00421	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—malignant glioma	4.33e-05	0.00419	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP2B6—malignant glioma	4.3e-05	0.00415	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—PDGFB—malignant glioma	4.07e-05	0.00394	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—malignant glioma	4.03e-05	0.0039	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—BCHE—malignant glioma	3.86e-05	0.00373	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP2C18—malignant glioma	3.78e-05	0.00365	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP2C18—malignant glioma	3.73e-05	0.0036	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PPARG—malignant glioma	3.45e-05	0.00333	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CXCL8—malignant glioma	3.22e-05	0.00311	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL1B—malignant glioma	3.09e-05	0.00299	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CASP3—malignant glioma	3.09e-05	0.00298	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTT1—malignant glioma	3.05e-05	0.00295	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—PTGS1—malignant glioma	2.86e-05	0.00277	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—VEGFA—malignant glioma	2.62e-05	0.00253	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—BRAF—malignant glioma	2.57e-05	0.00248	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—TFRC—malignant glioma	2.52e-05	0.00243	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PTEN—malignant glioma	2.37e-05	0.00229	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC5A5—malignant glioma	2.31e-05	0.00223	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—TNF—malignant glioma	2.24e-05	0.00217	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—TFRC—malignant glioma	2.23e-05	0.00216	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC6A3—malignant glioma	2.2e-05	0.00213	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—MDM2—malignant glioma	2.15e-05	0.00208	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—RAF1—malignant glioma	2.15e-05	0.00207	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—RTEL1—malignant glioma	2.14e-05	0.00207	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTP1—malignant glioma	2.12e-05	0.00205	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTP1—malignant glioma	2.09e-05	0.00202	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC5A5—malignant glioma	2.05e-05	0.00198	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—BRAF—malignant glioma	1.97e-05	0.0019	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—MDM2—malignant glioma	1.65e-05	0.00159	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—RAF1—malignant glioma	1.64e-05	0.00159	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—TP53—malignant glioma	1.62e-05	0.00156	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—COX8A—malignant glioma	1.23e-05	0.00119	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ASMT—malignant glioma	1.05e-05	0.00101	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—RAF1—malignant glioma	9.98e-06	0.000964	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—BCAN—malignant glioma	9.83e-06	0.00095	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—RAF1—malignant glioma	8.84e-06	0.000854	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—IDH2—malignant glioma	7.92e-06	0.000766	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP2B6—malignant glioma	7.45e-06	0.00072	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—IDH1—malignant glioma	6.81e-06	0.000658	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SPHK1—malignant glioma	6.59e-06	0.000637	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP2C18—malignant glioma	6.46e-06	0.000624	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTT1—malignant glioma	5.22e-06	0.000505	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTGS1—malignant glioma	4.9e-06	0.000473	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—BCHE—malignant glioma	4.55e-06	0.00044	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC5A5—malignant glioma	4.5e-06	0.000434	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTP1—malignant glioma	3.62e-06	0.00035	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CAT—malignant glioma	3.52e-06	0.00034	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NCOR1—malignant glioma	3.33e-06	0.000321	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CAV1—malignant glioma	2.71e-06	0.000262	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CG—malignant glioma	2.47e-06	0.000239	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PPARG—malignant glioma	2.38e-06	0.00023	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CD—malignant glioma	2.17e-06	0.00021	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CB—malignant glioma	1.89e-06	0.000183	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTGS2—malignant glioma	1.88e-06	0.000181	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTEN—malignant glioma	1.64e-06	0.000158	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CA—malignant glioma	1.15e-06	0.000112	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AKT1—malignant glioma	9.43e-07	9.11e-05	CbGpPWpGaD
